Merck KGaA Archives - Pharmaphorum

Merck KGaA’s BTK drug reduces lesions in relapsing MS patients

https://pharmaphorum.com/news/merck-kgaas-btk-drug-reduces-lesions-in-relapsing-ms-patients/

Pfizer/Merck KGaA eye fast review for kidney cancer combo

https://pharmaphorum.com/news/pfizer-merck-kgaa-eye-fast-review-bavencio/

Curious2018: A thirst for innovation

https://pharmaphorum.com/views-and-analysis/curious2018-innovation-thirst/

J&J tops the pharma market cap charts – but for how long?

https://pharmaphorum.com/views-and-analysis/jj-tops-pharma-market-cap-charts-long/

P&G buys Merck KGaA’s consumer health unit for $4.2bn

https://pharmaphorum.com/news/pg-buys-merck-kgaas-consumer-health-unit-4-2bn/

Roche’s Ocrevus MS drug approved in EU

https://pharmaphorum.com/news/roches-ocrevus-ms-drug-approved-eu/

NHS funding for five MS drugs under threat

https://pharmaphorum.com/news/nhs-funding-five-ms-drugs-threat/

Merck KGaA/Pfizer’s Bavencio fails in stomach cancer trial

https://pharmaphorum.com/news/merck-kgaapfizers-bavencio-fails-stomach-cancer-trial/

Apitope announces IPO to fund MS drug development

https://pharmaphorum.com/news/apitope-announces-ipo-fund-ms-drug-development/

Search